Quantum
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, KarinCA, sox040713, TheHound, scottsmith
Search This Board: 
Last Post: 11/18/2018 8:33:07 PM - Followers: 757 - Board type: Free - Posts Today: 57

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

2017 MILESTONES:



Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

Quantum
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Current Report Filing (8-k) 11/13/2018 07:16:54 AM
IPIX News: Quarterly Report (10-q) 11/08/2018 05:03:44 PM
IPIX News: Current Report Filing (8-k) 10/24/2018 07:01:54 AM
IPIX News: Statement of Changes in Beneficial Ownership (4) 10/16/2018 04:17:40 PM
IPIX News: Statement of Changes in Beneficial Ownership (4) 10/15/2018 06:20:16 PM
PlusOneCoin Top Posts
#248646  Restored Nice summary of Brilacidin for Ulcerative Proctitis. farrell90 11/13/18 09:44:36 PM
#248211   Have to give Leo credit for surviving this Rdunn88 11/09/18 10:17:12 AM
#247500  Restored ALSO...from BP Due Diligence point of view... HAVING Justfactsmam 11/04/18 09:02:57 AM
PostSubject
#248512  Sticky Note Top issues. oldtimer investor 11/12/18 07:30:47 PM
#245120  Sticky Note COMPARE FOR YOURSELF - 2012 to 2018 - DaubersUP 10/16/18 09:50:09 PM
#244935  Sticky Note Yes, a term sheet exists, as per the KarinCA 10/15/18 04:22:37 PM
#244735  Sticky Note Brilacidin as a Novel Inhibitor of Phosphodiesterase 4 LilKahuna 10/13/18 02:21:43 AM
#235000  Sticky Note IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patent sox040713 07/21/18 11:52:18 PM
#249136   That's what I expected. You don't have any examples. loanranger 11/18/18 08:41:43 PM
#249135   That's not what I was talking about. (See loanranger 11/18/18 08:40:46 PM
#249134   No. "Really? How about an example or two?" Snowy_Owl 11/18/18 08:38:50 PM
#249133   No requirement to PR a non event, a TheDane 11/18/18 08:33:06 PM
#249132   Tedious, and idle (5. of no real worth, TheDane 11/18/18 08:31:36 PM
#249131   Mediocre Leo did not PR missed milestones in jav0033 11/18/18 08:26:18 PM
#249130   "Yes, as you say they were his personal loanranger 11/18/18 08:22:53 PM
#249129   "I think a few comments may have ventured loanranger 11/18/18 08:17:28 PM
#249128   Yes, as you say they were his personal TheDane 11/18/18 08:12:42 PM
#249127   I believe that those shares would be restricted loanranger 11/18/18 07:56:09 PM
#249126   I think a few comments may have ventured Snowy_Owl 11/18/18 06:54:26 PM
#249125   What was there to figure out? Leo Snowy_Owl 11/18/18 06:50:22 PM
#249124   Will Leo give us something to be thankful snayeman 11/18/18 06:49:43 PM
#249122   Over an 84 day period subjects taking 100 georgejjl 11/18/18 06:23:57 PM
#249121   So he can gift shares to his synagogue. MrW 11/18/18 06:11:50 PM
#249119   I’m curious as to why you think monthly MrW 11/18/18 06:07:10 PM
#249118   "Not without the blessing of Leo and Dr.M. loanranger 11/18/18 06:04:23 PM
#249117   The premise is that Leo can pay the TheDane 11/18/18 06:03:27 PM
#249115   I'm curious as to what makes you think KarinCA 11/18/18 05:47:13 PM
#249114   How can you do one and then claim MrW 11/18/18 05:03:33 PM
#249113   When do they start? It will be an upgrade. MrW 11/18/18 04:59:46 PM
#249112   Totally wrong. If Leo could figure out a MrW 11/18/18 04:58:57 PM
#249111   How many people are applying for the CEO TheDane 11/18/18 04:29:24 PM
#249110   Now that I’ve seen this picture of Bertolino TheDane 11/18/18 04:25:51 PM
#249109   Although your mining example may be dismissed by Snowy_Owl 11/18/18 03:28:14 PM
#249108   “A successful End-of-Phase 2 FDA meeting for our georgejjl 11/18/18 03:16:36 PM
#249107   Reminds me of this rags to riches story:). kfcyahoo 11/18/18 03:16:15 PM
#249106   Celgene Corporation vs. Merck & Co. vs. Novartis georgejjl 11/18/18 02:51:55 PM
#249105   Most companies that have all their products successful petemantx 11/18/18 02:50:31 PM
#249104   Not without the blessing of Leo and Dr.M. Jhawker 11/18/18 02:48:51 PM
#249102   Seems the answer is out - they will Amatuer17 11/18/18 02:39:30 PM
#249101   In your example you considered large deposits of Amatuer17 11/18/18 02:38:06 PM
#249099   Probably the most critical issue for shareholders, or petemantx 11/18/18 02:04:56 PM
#249098   Clinical Remission in > 50% subjects (Day 42) georgejjl 11/18/18 01:49:28 PM
#249097   Look, no one is bidding. At all. Leo FarmaZutical 11/18/18 01:46:37 PM
#249096   For those that may find the Brilacidin UP KarinCA 11/18/18 01:15:53 PM
#249095   Could Celgene outbid Novartis and Pfizer for Innovation georgejjl 11/18/18 01:14:37 PM
#249094   Lets hope he over achieves with IPIX! He LilyGDog 11/18/18 01:06:44 PM
#249093   Yeah, seen that resume many times. The one kfcyahoo 11/18/18 01:05:28 PM
#249091   Thank you for providing this very informative piece. CallMeCrazy 11/18/18 12:30:05 PM
#249090   Nice problem. I give it first a probability PlentyParanoid 11/18/18 12:17:36 PM
#249089   So what has this have to do with JTORENCE 11/18/18 12:16:43 PM
#249088   When Dr. Arthur Peter Bertolino was Vice President georgejjl 11/18/18 12:11:26 PM
#249087   If no news this week I wouldn’t be snayeman 11/18/18 11:54:36 AM
#249086   As stated in my earlier comment I was Snowy_Owl 11/18/18 11:31:37 AM
#249085   My comment wasn't intended to be sarcastic. Snowy_Owl 11/18/18 11:25:40 AM
#249084   News this week? snayeman 11/18/18 11:23:33 AM
#249083   Do we know the severity of UP for LilKahuna 11/18/18 07:31:01 AM
#249082   If my comment about the fact that the loanranger 11/18/18 06:07:53 AM
#249081   Of course "There are many reasons some people loanranger 11/18/18 05:56:12 AM
PostSubject